BNBinod Nepal

Binod Nepal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Binod Nepal has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tribute to Professor Steve Scheiner

    by Upendra Adhikari, Binod Nepal, Yi Rao, Caleb Swain, Tuan Trinh, Wiktor Zierkiewicz, Mariusz Michalczyk

  • Open Access

    Identification of UCB-9721 as a potent inhibitor of MyoA, the essential class XIV myosin motor of apicomplexan parasites

    by Anne K Snyder, Filomena Tedesco, Anne Kelsen, Eddie Wehri, Binod Nepal, Jose Teixeira, Emmett Dews, Sachie Kanatani, Kyle Kasprzak, Jonathan Oliva, et al.

    The virulence of Toxoplasma gondii and other apicomplexan parasites relies on a unique form of cellular motility driven by MyoA, an unconventional class XIV myosin motor protein. To identify new chemical probes for investigating the molecular mechanisms of parasite motility, we screened over 50,000 small molecules for inhibitors of T. gondii MyoA (TgMyoA). The top hit from the screen, UCB-9721, is almost 40-fold more potent as an inhibitor of TgMyoA actin-activated ATPase activity than the previously described TgMyoA inhibitor, KNX-002, and 45-fold more potent at inhibiting parasite motility, with no detectable toxicity towards mammalian cells. UCB-9721 also inhibited the motility and/or growth of the related apicomplexan parasites Plasmodium falciparum, Cryptosporidium parvum, and Babesia duncani, suggesting that this compound will be a useful new chemical probe for studying motility and MyoA function in apicomplexan parasites more broadly. While UCB-9721 and KNX-002 were identified independently, they share a similar chemical scaffold. To determine why UCB-9721 is so much more potent than KNX-002 and to inform future development of this inhibitor class, we undertook comparative molecular docking analyses, targeted TgMyoA mutagenesis, and a directed structure-activity relationship analysis. The results identified the sulfonamide group of UCB-9721 and its hydrogen bond interactions with R249, E275 and a stabilized water network within the TgMyoA binding pocket as key to the compound’s increased potency. Further development of UCB-9721, informed by the results presented here, may transform this promising new chemical class into actionable drug development leads against this important group of human and animal pathogens.


  • Open Access

    Revisiting 2-Substituted-4(1 H )-Quinolones for Targeting the Plasmodium falciparum Cytochrome bc 1 Complex

    by Sovitj Pou, Katherine M. Liebman, Rolf W. Winter, Aaron Nilsen, Yuexin Li, Isaiah N. Lyche, Teresa M. Riscoe, Jemma Montgomery, Max J. Gramelspacher, Rozalia A. Dodean, et al.

    Quinolones substituted at the 2- and 3-positions with biaryl and diphenylether groups have been investigated for their antimalarial potential. ELQ-300, with a 3-position diphenyl ether, is at an advanced stage of preclinical development. Here, we synthesize the 2-position isomer of ELQ-300, i.e., HLQ-102, and describe synthetic procedures for preparing it that avoid the use of expensive catalysts and afford access to substituted quinolones bearing substituents in the 2-position as well as the benzenoid ring and with the critical 3-position CH3 group. We profile HLQ analogs for their antimalarial activity along with pharmacokinetics of the selected lead molecule. Cross-resistance patterns indicate that, like its predecessor, HLQ-102 targets the Qi site of the parasite cytochrome bc1 complex. This finding suggests the existence of two separate troughs in the target protein capable of accommodating such large structural features regardless of whether it is placed at the 2- or 3-positon of the quinolone ring.